Conference Description:

Welcome to the 8th Oncolytic Virotherapy Summit: Engineering Oncolytic Viruses Towards Revolutionary Anti-Cancer Immunotherapies

Recent years have seen highly promising and rapid advances in the pre-clinical development and clinical evolution of oncolytic virotherapies. They are increasingly being recognised as a therapy with huge potential to change the landscape for cancer immunotherapy. In the past 3 months alone, we have witnessed 20 new drugs entering into pre-clinical and clinical phases, and exciting FDA Fast Track Designation for Candel Therapeutics OV candidate - this community continues to maximize the impact of these hopeful therapies.

Unite with 100+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing and Controls (CMC) and Regulations to overcome the industry's largest and critical bottlenecks. Meet your community to hear how they address the major challenges facing the industry:

Investigate the Manufacturing Challenges and Approaches to Produce a Successful Oncolytic Virus to Ensure its Quality, Traceability, and Reliability
Understand the raw materials and supply chain management of your oncolytic virus and, explore the importance of stability of your viral vectors with insights from VYRIAD and Circio Bio

Optimize the Immunogenicity of Your Oncolytic Virus Candidate: Maximizing Effectiveness and Minimizing Side Effects in Cancer Treatment
Discuss the current immunogenicity studies to support FIM studies and assess the safety and efficacy of your oncolytic virus with insights from Boehringer Ingelheim and Omios Biologics

Review How to Bridge the Gap Between Pharma, Biotech and Investors to Facilitate the Growth and Development of This Field
Address the importance of collaboration and investment in advancing pharma and biotech innovations, and discuss the strategies for mitigating risks and maximizing returns on investment with insights from Candel Therapeutics and Valo Therapeutics

Discover the Potential of Using Combination Therapy for Improved Therapeutic Outcomes
Investigate the innovative combinations of oncolytic viruses with other therapeutic modalities as well as review the current pre-clinical and clinical studies demonstrating anti-tumor efficacy with insights from Replimune and Oncolys

Explore the Latest Clinical Data and How to Design Better Clinical Trials to Develop More Effective Oncolytic Virus's
Discussing the most up to date clinical data on advancements in oncolytic viruses and what are the possible breakthroughs and innovations we may see in the next year with insights from Lokon Pharma and Calidi Therapeutics

Register to Attend - https://ter.li/5drvrm

View Full Event Guide - https://ter.li/g866cl

Tickets: https://go.evvnt.com/1948756-2?pid=154
Time: 9:00 AM - 6:00 PM

Prices:
Drug Developer Pricing | Conference + Focus Day: USD 4297.00,
Drug Developer Pricing | Conference Only: USD 2999.00,
Academic Pricing | Conference + Focus Day: USD 3697.00,
Academic Pricing | Conference Only: USD 2599.00,
Solution and Service Provider Pricing | Conference + Focus Day: USD 5297.00,
Solution and Service Provider Pricing | Conference Only: USD 3799.00

Speakers: Angelica Loskog | Chief Executive Officer | Lokon Pharma AB, Antonio Santidrian | Global Head of R and D | Calidi Biotherapeutics Inc., Boris Minev | Interim Chief Medical Officer and President - Medical and Scientific Affairs | Calidi Biotherapeutics Inc., Elie Hanania | Vice President of Process Development - Viral Vector Technologies | Avid Bioservices Inc., Eric Quemeneur | Vice President and Chief Scientific Officer | Transgene, Erik Digman Wiklund | Chief Executive Officer | Circio Bio, Francesca Barone | CSO | Candel Therapeutics, Grey Wilkinson | Senior Director of Translational Science | Imugene, Heba Nowyhed | Chief Scientific Officer | IconOVir Bio, Hemanshu Shah | CBO | Valo Therapeutics Ltd., Johanna Kaufmann | Executive Vice President - Oncology | Codagenix, Inc., Kevin Maskell | Director - Research and Co-founder | Bioarchitech, Khalid Shah | Vice Chairman, Professor and Director - Stem Cell, Translational Immunotherapy | Brigham and Women's Hospital at Harvard Medical School, King Lee | Vice President | CaroGen Corporation, Megan Taylor | Researcher | Beacon, Michael Franti | Director and Head of Regenerative Medicine, Viral Platform, Drug Metabolism, and Pharmacokinetics | Boehringer Ingelheim, Mohamed Hammad | Assistant Professor - Research | City of Hope, Paul Hallenbeck | Founder, President, Chief Executive, and Scientific Officer | Seneca Therapeutics Inc., Paul Peter Tak | President, Chief Executive Officer, and Board Director | Candel Therapeutics, Praveen Bommareddy | Senior Director - Translational Research | Replimune, Richard Dambra | Viral Platforms, Drug Metabolism, and Pharmacokinetics Scientist | Boehringer Ingelheim RCV GmbH and Co KG, Ryan Davies | Chief Executive Officer | CancerVAX, Sarah-Kim Friedrich-Becker | Senior Principal Scientist | Abalos therapeutics, Sari Pesonen | Chief Scientific Officer | Valo Therapeutics Ltd., Sheryl Tran | Sr. Director of Quality and Compliance | VYRIAD, Steve Thorne | Chief Scientific Officer | KaliVir Immunotherapeutics, Talia Biran | President | Oncolys BioPharma Inc., Timur Yarovinsky | Vice President - Discovery, Director of Immunology | CaroGen Corporation, Tony Reid | CEO | EpicentRx, William Jackson | Senior Scientist | Bioarchitech